ozempic glp 1 agonist Another Weight-Loss Trial Win for Weekly GLP-1 Drug Is GLP-1 Safe for Weight

Description

D.DavisE

Sun Y, Jin J, Zhu A, et al

Back Lund, PK, Goodman, RH, Jacobs, JW, Habener, JF (July 1980) 'Glucagon precursors identified by immunoprecipitation of products of cell-free translation of messenger RNA', Diabetes , 29, 583-86

Of those 161 patients, 16 (10%) experienced recurrent acute pancreatitis after GLP-1 receptor agonist therapy (mean duration 10.8 7.2 months): 6 (38%) were caused by the GLP-1 receptor agonist (as clinically determined by the treating medical team), three (18%) were due to hypertriglyceridemia, two (12%) due to alcohol use, one (6%) due to another oral hypoglycemic agent, one (6%) due to ampulla stenosis, and three (19%) were idiopathic

Data indicate that participants receiving oral amycretin achieved an average weight loss of 13.1% after 12 weeks, which is substantially greater than the 1.1% weight loss observed in the placebo group [128]